Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study

Drug Category : Array
Conference Category : Array
Lead Author : Jurczak W, et al.
Published Date : 18/09/2021
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2021/09/Jurczak-iwCLL-2021-UNITY-CLL-9.19.21-Rev.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top